Last reviewed · How we verify
Peripheral arterial disease
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Peripheral arterial disease patent landscape — cliff calendar, originator estates, attackable patents
- Peripheral arterial disease treatment landscape brief
- Peripheral arterial disease treatment updates RSS
Frequently asked questions about Peripheral arterial disease
What drugs treat Peripheral arterial disease?
Tracked treatments include Xarelto.
What is the treatment for Peripheral arterial disease?
Standard treatment for Peripheral arterial disease includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Peripheral arterial disease patent cliff · Peripheral arterial disease CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing